Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

New study to examine genomics of anti-platelet therapy after coronary interventions

Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.

29 Jul 2016

'Novel' analysis addresses antiplatelet benefits in real-world CHD patients

Researchers demonstrate a means of gauging the effects of drugs tested in randomised trials in real-world patients.

28 Jun 2016

CYP2C19 gene variants undermine clopidogrel stroke prevention

The first look at CYP2C19 mutations in the context of a randomised controlled trial has confirmed suspicions that they affect the efficacy of clopidogrel in patients with acute stroke.

24 Jun 2016

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications.

22 May 2016

Younger women more likely to experience one-year adverse cardiovascular events after PCI

Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. The PROMETHEUS study found that outcomes for both men and women post-PCI are dependent on their baseline risk factors, not their sex.

9 May 2016

UPMC uses simple gene test to personalize medications for patients undergoing heart catheterization

Patients who go to UPMC Presbyterian for heart catheterization and who receive a stent to treat clogged arteries are now being screened with a simple blood test to determine if they have a gene variant that makes them less likely to respond to a blood-thinning medication commonly prescribed after the procedure.

11 Feb 2016

New study finds efficacy of novel intravenous blood thinner in women

Percutaneous coronary intervention (PCI) is a staple of modern day medicine in which cardiologists place a stent in a blood vessel around the heart in order to restore blood flow in people with heart disease. Blood thinners allow for the procedure to be completed with a reduced risk of certain complications such as clots.

18 Jan 2016

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research.

7 Dec 2015

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

For the first time, ESC Guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS).

29 Aug 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Researchers conducted a prospective observational study in elderly patients and adult patients receiving antiplatelet therapy who presented with mild head injury at two trauma hospitals in Vienna: the Trauma Hospital Meidling and the Donauspital.

7 Jul 2015

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data.

2 Jun 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Among patients with symptomatic intracranial arterial stenosis (narrowing of an artery inside the brain), the use of a balloon-expandable stent compared with medical therapy (clopidogrel and aspirin) resulted in an increased of stroke or transient ischemic attack (TIA), according to a study in the March 24/31 issue of JAMA.

25 Mar 2015

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases.

24 Feb 2015

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).

18 Nov 2014

Clopidogrel News and Research

New study to examine genomics of anti-platelet therapy after coronary interventions

'Novel' analysis addresses antiplatelet benefits in real-world CHD patients

CYP2C19 gene variants undermine clopidogrel stroke prevention

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Younger women more likely to experience one-year adverse cardiovascular events after PCI

UPMC uses simple gene test to personalize medications for patients undergoing heart catheterization

New study finds efficacy of novel intravenous blood thinner in women

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

ESC Congress to highlight results from global trials in six press conferences

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Substantial pharmacogenetic information available on cardiovascular drugs

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News